Ocugen (OCGN) EGM 2026 summary
Event summary combining transcript, slides, and related documents.
EGM 2026 summary
5 Oct, 2026Opening remarks and agenda
Reconvened special meeting followed the September 21, 2026, adjournment; meeting held virtually to expand stockholder access and participation.
Agenda and conduct rules governed proceedings; stockholders could submit questions online, limited to agenda items.
July 27, 2026, was the voting record date; eligible holders could inspect the stockholder list and meeting documents online.
Specific resolutions to be voted on
Item 1 proposed amending the charter to increase authorized common stock by 250 million shares.
Item 2 sought authority to adjourn if needed to solicit additional proxies; it was approved before the September 21 adjournment.
Corporate governance
James J. Wright of American Election Services, representing Broadridge Financial Solutions, served as independent inspector of election.
Inspector reported representation of one-third of outstanding voting power, establishing a quorum.
Latest events from Ocugen
- Share increase proposal lacked approval; meeting adjourned for further voting on October 5, 2026.OCGN
EGM 2026 - Late-stage gene therapies for major eye diseases advance toward BLA filings, with cash runway into 2028.OCGN
H.C. Wainwright 28th Annual Global Investment Conference - Shareholders will vote to increase authorized shares to support growth and commercialization.OCGN
Proxy filing - Pivotal gene therapy trials for RP and Stargardt aim for global launches by 2028.OCGN
Canaccord Genuity's 46th Annual Growth Conference - FDA cleared OCU410 phase III; $130M financing extends cash runway to 2028 amid going concern risk.OCGN
Q2 2026 - Vote on a 250 million share increase and meeting adjournment is recommended for approval.OCGN
Proxy filing - Vote sought to increase authorized shares by 250M to support growth and strategic flexibility.OCGN
Proxy filing - Vote sought to increase authorized shares by 250 million to support growth and financing flexibility.OCGN
Proxy filing - Late-stage gene therapies for major retinal diseases advance toward global approvals by 2028.OCGN
Piper Sandler Virtual Ophthalmology Day